The ghosts of JPMs past: How 20 years of deals, scandal, and science have shaped health care
Biotech is celebrating a platinum anniversary next week: 20 years since J.P. Morgan took over…
Category: biotechnology
STAT Plus: Biotech 2020 preview: Takeover targets, notable drug launches, and genome editing readouts
Hello, Biotech 2020. True, we’re already six days into the new year, but the first…
STAT Plus: The biotech scorecard for the first quarter: 14 stock-moving events to watch
Here is STAT’s Biotech Scorecard, our regular ledger of stock-moving biotech events, for the first…
STAT Plus: STAT’s guide to the most important, beneficial drugs approved in the past decade
The new year will end in a zero, making this a perfect opportunity to look…
STAT Plus: Crash and burn: The four biggest biopharma failures of 2019
In biotech, companies fail for a lot of reasons. The science might not quite work,…
3 trends in biotech to watch in 2020
For biotech, 2019 ended like the penultimate episode of a prestige TV show. We got…
STAT Plus: Sarepta sells international rights to Duchenne gene therapy to Roche
Sarepta Therapeutics said Monday that it will receive $1.15 billion in cash and an equity…
STAT Plus: Creating Pig3.0, the world’s most CRISPR’d animal, raises hopes of transplantable organs
A biotechnology company that is trying to create CRISPR-edited pigs so their organs could be…
Maraganore victorious in best biopharma CEO tally; Vounatsos tops worst list
Polls are closed and the votes have been counted. STAT readers have crowned the best…
Listen: The decade in breakthrough drugs, the year in bad CEOing, and the viruses that cure disease
Which drug defined the decade? Who’s the worst CEO in biopharma? And how does gene…
STAT Plus: Cutting-edge therapies promise one-time cures, but not without risk. Can biotech make them safer?
When Dr. Akshay Sharma sits down with his sickle cell disease patients to discuss potentially…
And now, your nominees for worst biopharma CEO of 2019. Let the voting begin!
I feel a touch of shame admitting that I enjoy compiling my annual list of…
STAT Plus: Axsome’s depression drug succeeds in late-stage trial
An experimental pill from Axsome Therapeutics had a rapid and significant effect on major depression…
Here are the nominees for best biopharma CEO of 2019. Vote for your favorite!
People often ask me how I select the nominees for best biopharma CEO of the…
FDA approves Amarin fish-oil-derived drug to prevent heart attacks and strokes
The Food and Drug Administration on Friday expanded the approval of Vascepa, a fish-oil-derived medicine,…
STAT Plus: The good, the bad, and the really, really ugly behind Sarepta’s drug approval
What does it all mean now that the Food and Drug Administration has issued a…
STAT Plus: Biotech veteran Chris Garabedian on Sarepta’s legacy and Biogen’s future at the FDA
This September marked the third anniversary of a pivotal moment in biotech. Back in 2016,…
FDA changes course on Sarepta’s once-rejected muscular dystrophy drug
The Food and Drug Administration reversed its decision on a treatment for Duchenne muscular dystrophy…
STAT Plus: Something Ventured: Akrevia Therapeutics and three other startups got venture funding a year ago. Did it help them do what they said it would?
This story is part of STAT’s quarterly series Something Ventured, which looks at early-stage startups….
STAT Plus: Bristol-Myers CMO on cell therapies: ‘This is the best time to be in drug development’
ORLANDO, Fla. — In June, Dr. Samit Hirawat was appointed chief medical officer of Bristol-Myers…
STAT Plus: Vindicated. New J&J CAR-T myeloma data confirm strong efficacy, ease doubts raised by Chinese version
ORLANDO, Fla. — One year ago, a Chinese scientist stepped up to a podium at…
STAT Plus: New data show Bluebird, Bristol CAR-T drug could be pioneering myeloma therapy. Competitors may be close behind
ORLANDO, Fla. — On the eve of a major blood disease research meeting here, Bluebird…
Families are reeling after FDA rejects therapy for kids born without a thymus gland
When Charlie Luckesen turned 2 the Wednesday before Thanksgiving, his family celebrated with a golden…
STAT Plus: Acquisitions, not Congress, will chart biotech’s course in 2020, experts predict
Washington has never before been so focused on lowering prescription drug prices. But these biotech…
Listen: Biogen’s big reveal, hot takes on Alzheimer’s, & the science of one-eyed sheep
How do you know if a “positive” study is positive? And what if clinical trial…
STAT Plus: Veritas, genetics company founded by George Church, suspends U.S. operations
Veritas Genetics, the Boston-based personal genome testing company co-founded by noted Harvard Medical School professor…
STAT Plus: More than 100 small biotech CEOs sound off against Pelosi’s signature drug pricing bill
WASHINGTON — Nearly 150 CEOs of emerging biotech companies are sending a unified, stark message…
Aurinia’s drug to treat autoimmune kidney disease hits its goals in late-stage trial
Aurinia Pharmaceuticals (AUPH) said Wednesday evening that an experimental medicine used to treat patients with…
STAT Plus: 4 questions key to making sense of new data on Biogen’s resurrected Alzheimer’s drug
The annual Alzheimer’s research meeting known as CTAD was supposed to be a snoozefest this…
STAT Plus: Congress is hoping for another major medical research bill. But pharma’s not nearly as excited as before
WASHINGTON — The bipartisan duo behind a 2016 law that poured billions into medical research…
STAT Plus: This invite-only club is grooming new biotech CEOs — and helping make them less lonely, too
Steve Woit runs an exclusive, confidential, invite-only club for biotech CEOs — but it’s not…
STAT Plus: Startup Spotlight: Juno, Vir alum starts a new immunotherapy company
A Juno Therapeutics and Vir Biotechnology founder may be about to launch a new company…
STAT Plus: Pharmalittle: Feds probe drug makers for flooding communities with opioids; States proceeding with importation
And so, another working week will soon come to an end, but earlier than usual,…
STAT Plus: Enlight Biosciences was going to ‘transform pharma R&D.’ What happened?
Unlike most biotech startups, Enlight Biosciences was never expected to make any drugs. Instead, the…
.jpg)
Global Blood secures FDA approval for new pill to treat sickle cell disease
The Food and Drug Administration on Monday approved a once-daily pill for sickle cell disease…
STAT Plus: Facing bottlenecks in manufacturing cell therapies, Boston leaders plan to build their own
A group of leading Boston-area universities, hospitals, and corporations will create a new center for…
With $9.7 billion acquisition, Novartis bets that heart drugs are coming back
Novartis’ $9.7 billion acquisition of The Medicines Company, which the companies announced Sunday after days…
Listen: Warren’s awkward home front, the ethics of treating dwarfism, and the sound of STAT Summit
Can Sen. Elizabeth Warren ever go home again? Is it ethical to make little people…
STAT Plus: Watch: The state of biotech at time of innovation — and high prices
CAMBRIDGE, Mass. — We live in an age of miracles, but they come at a…
Biogen’s top scientist nearly dares FDA not to approve Alzheimer’s drug
Biogen’s top scientist offered unflinching support Thursday for the efficacy of the company’s controversial Alzheimer’s…
STAT Plus: ‘The industry has earned it’: Three CEOs own up to biopharma’s bad reputation
CAMBRIDGE, Mass. — Biopharma’s reputation is, objectively speaking, the worst. And on Thursday, several biotech…
Gilead CEO Daniel O’Day says company is in an ‘acquisitive mode’
CAMBRIDGE, Mass. — Daniel O’Day, in his eight months on the job as CEO of…
FDA approves Alnylam’s Givlaari, second-ever drug based on RNAi
The FDA has approved the second-ever drug based on a Nobel prize-winning technique known as…
STAT Plus: Biotech venture capitalists form a lobbying coalition to join the drug pricing debate
A shorter version of this story first appeared in D.C. Diagnosis, STAT’s weekly newsletter about…
First CRISPR treatment for blood diseases shows early benefits in two patients
The first two patients to receive a CRISPR-based treatment for the inherited blood disorders sickle…
STAT Plus: Novo Nordisk’s parent company to launch research incubator in Boston
Novo Holdings, the investment firm behind pharmaceutical giant Novo Nordisk, is committing $25 million over…